FDA delay means BeiGene, Novartis must wait longer for cancer drug decision
The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the […]
The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the […]
El estudio era pequeño y los expertos dicen que hay que replicarlo. Pero para 18 pacientes oncológicos, el resultado produjo “lágrimas de felicidad”.
The study was small, and experts say it needs to be replicated. But for 18 people with colorectal cancer, the outcome led to “happy tears.”
Recently, NBC News’ Today did a profile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the […]
A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which […]
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights […]
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights […]
Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed […]
Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Bispecific antibodies (bsAbs) are designed to recognise […]
Stallergenes Greer has teamed up with Aptar Pharma to develop a digital dimension for its allergen immunotherapy (AIT) products that it hopes will improve the […]
In less than two years, Egle Therapeutics launched, partnered with Takeda Pharmaceutical, and found its first cancer targets. Now the startup has €40M in Series […]
Un número cada vez mayor de pacientes con cáncer, especialmente los de mama y pulmón, se libran del temido tratamiento en favor de otras alternativas.
Un número cada vez mayor de pacientes con cáncer, especialmente los de mama y pulmón, se libran del temido tratamiento en favor de otras alternativas.
A growing number of cancer patients, especially those with breast and lung cancers, are being spared the dreaded treatment in favor of other options.
Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes […]
Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. […]
Called Novasenta, the company is focused on the tumor microenvironment and will leverage its machine-learning platform to pinpoint targets for drug development. It aims to […]
Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the […]
GlaxoSmithKline drug Jemperli is now FDA approved for treating solid tumors throughout the body as long as they have a particular genetic signature. Expanding the […]
In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic research at UK company Adaptimmune which is transforming […]
Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses […]
Several companies are developing immunotherapies targeting the “don’t eat me” cancer protein CD47. Arch Oncology, which is developing drugs with features that could set them […]
Shots: The US FDA has approved Ventana MMR RxDx panel to identify endometrial cancer patients who are eligible for treatment with GSK’s Jemperli (monothx.) that […]
Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer. Catherine Longworth spoke to CEO […]
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need […]
ImaginAb has signed a deal with Pfizer, which it hopes will help it to gather information necessary for approval of its tumour imaging agent as […]
The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and […]
Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy will likely fail to produce results in […]
Liquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will be used to expand commercial opportunities. ANGLE’s […]
The company hopes to use the money to bring its T-cell antigen coupler cell therapy technology – currently in preclinical development – into human clinical […]
Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics. The companies signed a deal to develop cancer immunotherapies […]
Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates Merck has forged a collaboration with Boston-based Dewpoint Therapeutics to treat HIV using Dewpoint’s […]
Copyright © 2024 | WordPress Theme by MH Themes